ArticleCancer discovery2021
Proteomic Screens for Suppressors of Anoikis Identify IL1RAP as a Promising Surface Target in Ewing Sarcoma.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 104 citations in OpenAlex.
- Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial.Nature medicine · 2026Trial
- Surface and global proteomics identify ROR2 and other proteins as potentially actionable immunotherapeutic targets in osteosarcoma.Cell reports · 2026Article
- IL1RAP Antibody-Drug Conjugates Potently Target Primary and Metastatic Diseases in Multiple Oncofusion-Driven Cancers.Cancer discovery · 2026Article
- Chondroitin sulfate shapes the unfolded protein response in osteosarcoma to sustain cancer cell survival during ER stress.Cell death & disease · 2026Article
- Sarcoma metastasis: distinct biological principles beyond the carcinoma paradigm.Cancer metastasis reviews · 2026Review
- Circumventing Ewing sarcoma tumor microenvironment resistance by IL1RAP CAR-modified TGFβ1-imprinted natural killer cells in combination with IL-15 agonist and anti-GD2 antibody.Journal for immunotherapy of cancer · 2026Article
- A targetable FTO/SLC7A11/CBS/CTH axis controls cysteine metabolism, growth and survival in NSCLC.Science advances · 2026Article
- Review
- Co-targeting cystathionine gamma-lyase and mTOR: a promising therapeutic strategy in clear cell ovarian cancer.BMC cancer · 2026Article
- YEATS2 promotes DNA repair and induces anoikis resistance by enhancing chromatin accessibility to drive prostate cancer metastasis.Oncogene · 2026Article
- Mithramycin alters EWS::FLI1 DNA binding and RNA polymerase II processivity to inhibit nascent transcription.Nature communications · 2026Article
- An anoikis-based risk model predicts outcomes and is associated with the immune microenvironment in adrenocortical carcinoma.Frontiers in molecular biosciences · 2026Article
- Constructing anoikis-related signatures in glioma and identifying PLAU as a new prognostic biomarker.BMC medical genomics · 2025Article
- Spatial Profiling Identifies Tumor-Associated Stroma Enrichment and MIF as Potential Immunotherapy Targets in Primary Ewing Sarcomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Unraveling the anoikis-cancer nexus: a bibliometric analysis of research trends and mechanisms.Future science OA · 2025Article
- Polyamine Depletion by D,L-α-Difluoromethylornithine Inhibits Ewing Sarcoma Metastasis by Inducing Ferroptosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- New Approaches to Investigate Novel Agents in Ewing Sarcoma: A Report From the Children's Oncology Group Bone Tumor Committee.Pediatric blood & cancer · 2025Review
- Explore the role of CBS in stomach adenocarcinoma based on the sulfur-containing amino acid metabolism network.Scientific reports · 2025Article
- Anoikis resistance in Cancer: Mechanisms, therapeutic strategies, potential targets, and models for enhanced understanding.Cancer letters · 2025Review
- Host transcriptome profiling for resistance against lumpy skin disease (LSD).BMC research notes · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
33 authors at 7 institutions in 6 countries.
Hai-Feng ZhangDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Christopher S HughesDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0002-6980-4459
Wei LiCenter for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School, Pittsburgh, Pennsylvania.
Jian-Zhong HeInstitute of Oncologic Pathology, Shantou University Medical College, Shantou, Guangdong, China.ORCID 0000-0003-1256-472X
Didier SurdezINSERM U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, 75005 Paris, France.ORCID 0000-0002-7118-7859
Amal M El-NaggarDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0002-3202-6171
Hongwei ChengDepartment of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.
Anna PrudovaDepartment of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.
Alberto DelaidelliDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Gian Luca NegriCanada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.ORCID 0000-0001-7722-8888
Xiaojun LiDepartment of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.
Maj Sofie Ørum-MadsenVancouver Prostate Centre, Vancouver, British Columbia, Canada.
Michael M LizardoDepartment of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.
Htoo Zarni OoVancouver Prostate Centre, Vancouver, British Columbia, Canada.
Shane ColborneCanada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.
Taras ShypDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Renata Scopim-RibeiroDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Colin A HammondTerry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
Anne-Chloe DhezDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Sofya LangmanDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Jonathan K M LimDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Sonia H Y KungVancouver Prostate Centre, Vancouver, British Columbia, Canada.
Amy LiDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Anne SteinoDepartment of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.
Mads DaugaardVancouver Prostate Centre, Vancouver, British Columbia, Canada.ORCID 0000-0001-8383-055X
Seth J ParkerDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0003-0012-8058
Ramon I Klein GeltinkDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0003-4610-3059
Rimas J OrentasSeattle Children's Research Institute, Seattle, Washington.ORCID 0000-0002-6310-3467
Li-Yan XuInstitute of Oncologic Pathology, Shantou University Medical College, Shantou, Guangdong, China.ORCID 0000-0002-1618-4292
Gregg B MorinCanada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.ORCID 0000-0001-8949-4374
Olivier Delattre *INSERM U830, Equipe Labellisée LNCC, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, SIREDO Oncology Centre, Institut Curie Research Centre, 75005 Paris, France.
Dimiter S Dimitrov *Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School, Pittsburgh, Pennsylvania.ORCID 0000-0002-2258-1024
Poul H SorensenDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada. psor@mail.ubc.ca.
BC Cancer Agency · CAThe Prostate Centre · GBUniversity of British Columbia · CACanada's Michael Smith Genome Sciences Centre · CAInserm · FRShantou University · CNUniversity of Pittsburgh Medical Center · US
Funding
Understanding and Overcoming Resistance to Immunotherapies in Childhood CancersU54CA232568 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI MACKALL, CRYSTAL, MARIS, JOHN M · 2018 to 2022
$13.1MNCI NIH HHS U54 CA232568
Abstract
Cancer cells must overcome anoikis (detachment-induced death) to successfully metastasize. Using proteomic screens, we found that distinct oncoproteins upregulate IL1 receptor accessory protein (IL1RAP) to suppress anoikis. IL1RAP is directly induced by oncogenic fusions of Ewing sarcoma, a highly metastatic childhood sarcoma. IL1RAP inactivation triggers anoikis and impedes metastatic dissemination of Ewing sarcoma cells. Mechanistically, IL1RAP binds the cell-surface system X
Indexed as
AnoikisInterleukin-1 Receptor Accessory ProteinSarcoma, EwingAdultCell Line, TumorChildHumansProteomicsReceptors, Interleukin-1IL1RAP protein, humanInterleukin-1 Receptor Accessory ProteinReceptors, Interleukin-1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.